<DOC>
	<DOCNO>NCT02683187</DOCNO>
	<brief_summary>This study do determine role hormone , glucagon-like peptide 1 ( GLP-1 ) , insulin secretion study GLP-1 work diabetic individual compare non-diabetic individual , fast condition . GLP-1 naturally occur hormone make intestine . It release circulate blood eat help control blood glucose level increase insulin secretion cell pancreas . However , exact method GLP-1 cause insulin secretion GLP-1 activity change diabetic person remain unclear . This research do address question well understand function GLP-1 . In research , investigator use synthetic form Exendin-9 determine effect GLP-1 insulin secretion diabetic non-diabetic person . Exendin-9 act blocker GLP-1 action , allow u study specific effect GLP-1 hormone . Exendin-9 investigational compound , mean still test research study approve U.S. Food Drug Administration ( FDA ) . In study , investigator also use drug Sitagliptin , FDA-approved drug treatment type 2 diabetes mellitus . In study , use Sitagliptin consider investigational since use treatment diabetes instead use understand GLP-1 work well understand medication like Sitagliptin work patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>DPP4 Inhibition &amp; Beta Cell Function</brief_title>
	<detailed_description />
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Healthy adult age 3560 year Male female Ability speak understand English Rheumatoid arthritis Inflammatory bowel disease Unstable angina uncompensated heart failure Pulmonary disorder , include COPD asthma Malabsorptive GI disease , celiac disease , gastric bypass Significant hepatic disease Renal insufficiency ( eGFR &lt; 60 mL/kg/min ) Anemia ( hematocrit &lt; 34 % ) measure screen visit Uncontrolled hypertension Pregnant females Consumption daily medication alter glucose metabolism GI function ( glucocorticoid , psychotropics , narcotic , metoclopramide ) Consumption injection insulin Apparent sensitivity study peptide determine skin test</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>insulin secretion</keyword>
	<keyword>GLP-1</keyword>
	<keyword>alpha cell</keyword>
	<keyword>paracrine effect</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
</DOC>